BIOXYTRAN INC News

Bioxytran Inc Welcomes New Expert to Board, Modifies Stock Rights

TipRanksApr 20 04:44

Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now

Yahoo FinanceApr 3 19:00

Bioxytran Gains as FDA Clears Clinical Trial for Lead Asset

Seeking AlphaAug 24, 2023 22:13

Bioxytran Announces FDA Clearance of Its IND Application for ProLectin-M in Clinical Trials

Stockhouse Aug 24, 2023 21:00

Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19...

Stockhouse Aug 8, 2023 19:00

Bioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory Board

Stockhouse Jul 31, 2023 19:00

Bioxytran Peer-Reviewed Journal in "Vaccines" Contains Mechanism Capable of Targeting Future COVID-19 Mutations

Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most symptoms by day 7Galectin antagonist acts as an entry inhibitor for use in treatme

GlobeNewswireJun 27, 2023 19:00

Bioxytran Expands Institutional Investor Base With an Additional $500,000 Equity Investment

- Funding in place to meet next regulatory milestone BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the "Company"), a clinical stage biotechnology company developi

GlobeNewswireJun 12, 2023 21:00

Bioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical Trials

BOSTON, MASSACHUSETTS, April 19, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the "Company"), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral dise

GlobeNewswireApr 19, 2023 21:11

Bioxytran Announces Positive Phase 2 Trial Results Were Featured in "Vaccines" a Peer-Reviewed Journal

Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most symptoms by day 7Galectin antagonist acts as an entry inhibitor for use in treatme

GlobeNewswireMar 29, 2023 19:08

ProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial Virus

Activity in Influenza and Respiratory Syncytial Virus highlights the broad- spectrum antiviral potential of ProLectin-M BOSTON, MASSACHUSETTS, Feb. 28, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQ

GlobeNewswireFeb 28, 2023 21:07

Nature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral Drug

BOSTON, MASSACHUSETTS, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19, other viral

GlobeNewswireFeb 22, 2023 21:01

Bioxytran to Appear on ClearThink IR’s Virtual Live Event

- Wednesday, February 15th, 2023 12:00 EST - Virtual Fireside Chat via Paltalk Platform BOSTON, MASSACHUSETTS, Feb. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the "Company"), a clin

GlobeNewswireFeb 14, 2023 22:06

Bioxytran Receives Approval to Initiate Trials With ProLectin-I

BOSTON, MASSACHUSETTS, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the "Company"), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19

GlobeNewswireFeb 6, 2023 22:06

Bioxytran Shares Rise 20% on Trial Results for Covid-19 Drug

By Denny Jacob Bioxytran Inc. shares rose 20% to 46 cents Wednesday after the company said a Phase 2 clinical trial of its Covid-19 drug resulted in positive topline safety and efficacy results. The

Dow JonesDec 29, 2022 01:13

Bioxytran Chewable Drug for COVID-19 Meets Phase 2 Trial's Goals

Seeking AlphaDec 28, 2022 20:43

Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial

Trial meets endpoints in safety and efficacyIND Letter from the CDSCO to optimize dosageEstablishment of an Indian Subsidiary to commercialize ProLectin-M BOSTON, MASSACHUSETTS, Dec. 28, 2022 (GLOBE NEWSWIRE)

GlobeNewswireDec 28, 2022 20:01

Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization

BOSTON, MASSACHUSETTS, Dec. 14, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral

GlobeNewswireDec 14, 2022 20:00

Bioxytran Interview at the Emerging Growth Conference

Wednesday, December 14, 2022 1:45pm –2:15pm ESTDiscussion of Clinical Trial Results BOSTON, MASSACHUSETTS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB:BIXT) (the "Company"), a clinical stage biotechnology

GlobeNewswireDec 12, 2022 22:46

Bioxytran Receives Approval to Optimize Dosage in COVID-19 Patients

BOSTON, MASSACHUSETTS, Dec. 08, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the "Company"), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and o

GlobeNewswireDec 8, 2022 20:06